{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:38:53Z","timestamp":1790995133112,"version":"4.1.0"},"reference-count":153,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["US Cardiol"],"abstract":"<jats:p>Patients with atherosclerotic cardiovascular disease (ASCVD), such as those with a history of MI or stroke, are at high risk for morbidity and mortality associated with future cardiovascular events. Ideal management of these patients requires a multifactorial strategy for risk factor mitigation and prevention of additional cardiovascular events. Traditional management of secondary prevention patients involves lipid-lowering with statins, blood pressure control, and anti-platelet treatment. Several additional targets have been identified to optimize the secondary prevention of ASCVD, such as further lipid control, inflammation management, lifestyle and weight optimization, strict diabetes control, use of \u03b2-blockers, use of renin\u2013angiotensin\u2013aldosterone system inhibitors, vaccinations, and additional considerations of anti-thrombotic therapies. This review will describe the interventions associated with these targets, as well as the relevant research and indications for these therapies.<\/jats:p>","DOI":"10.15420\/usc.2024.33","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:59:33Z","timestamp":1745920773000},"source":"Crossref","is-referenced-by-count":6,"title":["Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease"],"prefix":"10.15420","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6994-2551","authenticated-orcid":false,"given":"Madelyn","family":"Hurwitz","sequence":"first","affiliation":[{"name":"School of Medicine, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-4734","authenticated-orcid":false,"given":"Olayinka J","family":"Agboola","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inova Schar Heart and Vascular Institute, Falls Church, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-4694","authenticated-orcid":false,"given":"Abhishek","family":"Gami","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-0318","authenticated-orcid":false,"given":"Marlene S","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-6954","authenticated-orcid":false,"given":"Salim S","family":"Virani","sequence":"additional","affiliation":[{"name":"Department of Medicine, The Aga Khan University, Karachi, Pakistan; Texas Heart Institute and Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7254-2077","authenticated-orcid":false,"given":"Garima V","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inova Schar Heart and Vascular Institute, Falls Church, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5130-7772","authenticated-orcid":false,"given":"Jaideep","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"ref0","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019. J Am Coll Cardiol 2020;76:2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010; PMID:\u00a033309175."},{"key":"ref1","unstructured":"Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics\u20142021 update: a report from the American Heart Association. Circulation 2021;143:e254\u2013743. https:\/\/doi.org\/10.1161\/CIR.0000000000000950; PMID:\u00a033501848."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Alberts MJ, Bhatt DL, Mas JL, et al. Three-year follow-up and event rates in the international REduction of atherothrombosis for Continued Health Registry. Eur Heart J 2009;30:2318\u201326. https:\/\/doi.org\/10.1093\/eurheartj\/ehp355; PMID:\u00a019720633.","DOI":"10.1093\/eurheartj\/ehp355"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Rapsomaniki E, Thuresson M, Yang E, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes 2016;2:172\u201383. https:\/\/doi.org\/10.1093\/ehjqcco\/qcw004; PMID:\u00a029474617.","DOI":"10.1093\/ehjqcco\/qcw004"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350\u20137. https:\/\/doi.org\/10.1001\/jama.2010.1322; PMID:\u00a020805624.","DOI":"10.1001\/jama.2010.1322"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Holtrop J, Bhatt DL, Ray KK, et al. Impact of the 2021 European Society for Cardiology prevention guideline\u2019s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease. Eur J Prev Cardiol 2024;31:zwae038. https:\/\/doi.org\/10.1093\/eurjpc\/zwae038; PMID:\u00a038324720.","DOI":"10.1093\/eurjpc\/zwae038"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines. Circulation 2023;148:e9\u2013119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168; PMID:\u00a037471501.","DOI":"10.1161\/CIR.0000000000001183"},{"key":"ref7","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484; PMID:\u00a034458905."},{"key":"ref8","unstructured":"Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425; PMID:\u00a031504439."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;37:1129\u201350. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016; PMID:\u00a033781847.","DOI":"10.1016\/j.cjca.2021.03.016"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mancini GBJ, O\u2019Meara E, Zieroth S, et al. 2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults. Can J Cardiol 2022;38:1153\u201367. https:\/\/doi.org\/10.1016\/j.cjca.2022.04.029; PMID:\u00a035961754.","DOI":"10.1016\/j.cjca.2022.10.008"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Singh RB, Rastogi SS, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 1992;304:1015\u20139. https:\/\/doi.org\/10.1136\/bmj.304.6833.1015; PMID:\u00a01586782.","DOI":"10.1136\/bmj.304.6833.1015"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"De Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet heart study. Circulation 1999;99:779\u201385. https:\/\/doi.org\/10.1161\/01.CIR.99.6.779; PMID:\u00a09989963.","DOI":"10.1161\/01.cir.99.6.779"},{"key":"ref13","unstructured":"Delgado-Lista J, Alcala-Diaz JF, Torres-Pe\u00f1a JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 2022;399:1876\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(22)00122-2; PMID:\u00a035525255."},{"key":"ref14","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34. https:\/\/doi.org\/10.1056\/NEJMoa1800389; PMID:\u00a029897866."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Tucker WJ, Fegers-Wustrow I, Halle M, et al. Exercise for primary and secondary prevention of cardiovascular disease: JACC Focus Seminar 1\/4. J Am Coll Cardiol 2022;80:1091\u2013106. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.004; PMID:\u00a036075680.","DOI":"10.1016\/j.jacc.2022.07.004"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Stewart RAH, Held C, Hadziosmanovic N, et al. Physical activity and mortality in patients with stable coronary heart disease. J Am Coll Cardiol 2017;70:1689\u2013700. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.017; PMID:\u00a028958324.","DOI":"10.1016\/j.jacc.2017.08.017"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Jeong SW, Kim SH, Kang SH, et al. Mortality reduction with physical activity in patients with and without cardiovascular disease. Eur Heart J 2019;40:3547\u201355. https:\/\/doi.org\/10.1093\/eurheartj\/ehz564; PMID:\u00a031504416.","DOI":"10.1093\/eurheartj\/ehz564"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Fan Y, Yu M, Li J, et al. Efficacy and safety of resistance training for coronary heart disease rehabilitation: a systematic review of randomized controlled trials. Front Cardiovasc Med 2021;8:754794. https:\/\/doi.org\/10.3389\/fcvm.2021.754794; PMID:\u00a034805309.","DOI":"10.3389\/fcvm.2021.754794"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Marzolini S, Oh PI, Brooks D. Effect of combined aerobic and resistance training versus aerobic training alone in individuals with coronary artery disease: a meta-analysis. Eur J Prev Cardiol 2012;19:81\u201394. https:\/\/doi.org\/10.1177\/1741826710393197; PMID:\u00a021450617.","DOI":"10.1177\/1741826710393197"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Dibben GO, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. Eur Heart J 2023;44:452\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehac747; PMID:\u00a036746187.","DOI":"10.1093\/eurheartj\/ehac747"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Dahabreh IJ, Paulus JK. Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis. JAMA 2011;305:1225\u201333. https:\/\/doi.org\/10.1001\/jama.2011.336; PMID:\u00a021427375.","DOI":"10.1001\/jama.2011.336"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation 2021;143:e763\u201383. https:\/\/doi.org\/10.1161\/CIR.0000000000000947; PMID:\u00a033486973.","DOI":"10.1161\/cir.0000000000000947"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Vaccarino V, Badimon L, Bremner JD, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41:1687\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehy913; PMID:\u00a030698764.","DOI":"10.1093\/eurheartj\/ehy913"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Meijer A, Conradi HJ, Bos EH, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. Gen Hosp Psychiatry 2011;33:203\u201316. https:\/\/doi.org\/10.1016\/j.genhosppsych.2011.02.007; PMID:\u00a021601716.","DOI":"10.1016\/j.genhosppsych.2011.02.007"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014;129:1350\u201369. https:\/\/doi.org\/10.1161\/CIR.0000000000000019; PMID:\u00a024566200.","DOI":"10.1161\/cir.0000000000000019"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005;165:2508\u201313. https:\/\/doi.org\/10.1001\/archinte.165.21.2508; PMID:\u00a016314548.","DOI":"10.1001\/archinte.165.21.2508"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Huffman JC, Beale EE, Celano CM, et al. Effects of optimism and gratitude on physical activity, biomarkers, and readmissions after an acute coronary syndrome: the gratitude research in acute coronary events study. Circ Cardiovasc Qual Outcomes 2016;9:55\u201363. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.115.002184; PMID:\u00a026646818.","DOI":"10.1161\/circoutcomes.115.002184"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Willett J, Achenbach S, Pinto FJ, et al. The tobacco endgame \u2013 eradicating a worsening epidemic: a joint opinion from the American Heart Association. Circulation 2021;144:e1\u20135. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054369; PMID:\u00a034036792.","DOI":"10.1161\/circulationaha.121.054369"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J Am Coll Cardiol 2015;66:1378\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2015.07.037; PMID:\u00a026383726.","DOI":"10.1016\/j.jacc.2015.07.037"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Johnson HM, Gossett LK, Piper ME, et al. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2010;55:1988\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2010.03.002; PMID:\u00a020236788.","DOI":"10.1016\/S0735-1097(10)61436-2"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86\u201397. https:\/\/doi.org\/10.1001\/jama.290.1.86; PMID:\u00a012837716.","DOI":"10.1001\/jama.290.1.86"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2022;8:CD014936. https:\/\/doi.org\/10.1002\/14651858.CD014936.pub2; PMID:\u00a035938889.","DOI":"10.1002\/14651858.CD014936"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Shahandeh N, Chowdhary H, Middlekauff HR. Vaping and cardiac disease. Heart 2021;107:1530\u20135. https:\/\/doi.org\/10.1136\/heartjnl-2020-318150; PMID:\u00a033574049.","DOI":"10.1136\/heartjnl-2020-318150"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Qasim H, Karim ZA, Rivera JO, et al. Impact of electronic cigarettes on the cardiovascular system. J Am Heart Assoc 2017;6:e006353. https:\/\/doi.org\/10.1161\/JAHA.117.006353; PMID:\u00a028855171.","DOI":"10.1161\/JAHA.117.006353"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"George J, Hussain M, Vadiveloo T, et al. Cardiovascular effects of switching from tobacco cigarettes to electronic cigarettes. J Am Coll Cardiol 2019;74:3112\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.067; PMID:\u00a031740017.","DOI":"10.1016\/j.jacc.2019.09.067"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Parikh NI, Pencina MJ, Wang TJ, et al. Increasing trends in incidence of overweight and obesity over 5 decades. Am J Med 2007;120:242\u201350. https:\/\/doi.org\/10.1016\/j.amjmed.2006.06.004; PMID:\u00a017349447.","DOI":"10.1016\/j.amjmed.2006.06.004"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Dansinger ML, Tatsioni A, Wong JB, et al. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med 2007;147:41\u201350. https:\/\/doi.org\/10.7326\/0003-4819-147-1-200707030-00007; PMID:\u00a017606960.","DOI":"10.7326\/0003-4819-147-1-200707030-00007"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Wu T, Gao X, Chen M, Van Dam RM. Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis. Obes Rev 2009;10:313\u201323. https:\/\/doi.org\/10.1111\/j.1467-789X.2008.00547.x; PMID:\u00a019175510.","DOI":"10.1111\/j.1467-789x.2008.00547.x"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Doumouras AG, Wong JA, Paterson JM, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study. Circulation 2021;143:1468\u201380. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052386; PMID:\u00a033813836.","DOI":"10.1161\/circulationaha.120.052386"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"N\u00e4slund E, Stenberg E, Hofmann R, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with previous myocardial infarction and severe obesity: a nationwide cohort study. Circulation 2021;143:1458\u201367. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.048585; PMID:\u00a033103469.","DOI":"10.1161\/circulationaha.120.048585"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Usman MS, Davies M, Hall ME, et al. The cardiovascular effects of novel weight loss therapies. Eur Heart J 2023;44:5036\u201348. https:\/\/doi.org\/10.1093\/eurheartj\/ehad664; PMID:\u00a037966486.","DOI":"10.1093\/eurheartj\/ehad664"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183; PMID:\u00a033567185.","DOI":"10.1056\/nejmoa2032183"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892; PMID:\u00a026132939.","DOI":"10.1056\/nejmoa1411892"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, et al. Pioneer 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 2019;42:1724\u201332. https:\/\/doi.org\/10.2337\/dc19-0749; PMID:\u00a031186300.","DOI":"10.2337\/db18-2-LB"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Knop FK, Aroda VR, Do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;402:705\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(23)01185-6; PMID:\u00a037385278.","DOI":"10.1016\/s0140-6736(23)01185-6"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 2021;44:765\u201373. https:\/\/doi.org\/10.2337\/dc20-1473; PMID:\u00a033397768.","DOI":"10.2337\/dc20-1473"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255\u201361. https:\/\/doi.org\/10.2337\/dc09-1914; PMID:\u00a020215461.","DOI":"10.2337\/dc09-1914"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038; PMID:\u00a035658024.","DOI":"10.1056\/nejmoa2206038"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563; PMID:\u00a037952131.","DOI":"10.1056\/nejmoa2307563"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027; PMID:\u00a039555826.","DOI":"10.1056\/nejmoa2410027"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022;327:138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619; PMID:\u00a035015037.","DOI":"10.1001\/jama.2021.23619"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"G\u00e6de P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383\u201393. https:\/\/doi.org\/10.1056\/NEJMoa021778; PMID:\u00a012556541.","DOI":"10.1056\/nejmoa021778"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"G\u00e6de P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580\u201391. https:\/\/doi.org\/10.1056\/NEJMoa0706245; PMID:\u00a018256393.","DOI":"10.1056\/nejmoa0706245"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720; PMID:\u00a026378978.","DOI":"10.1056\/nejmoa1504720"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925; PMID:\u00a028605608.","DOI":"10.1056\/nejmoa1611925"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389; PMID:\u00a030415602.","DOI":"10.1056\/NEJMoa1812389"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148\u201358. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511; PMID:\u00a033031522.","DOI":"10.1001\/jamacardio.2020.4511"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","DOI":"10.1056\/NEJMoa2022190"},{"key":"ref59","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303; PMID:\u00a031535829."},{"key":"ref60","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038; PMID:\u00a034449189."},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233; PMID:\u00a036331190.","DOI":"10.1056\/nejmoa2204233"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816; PMID:\u00a032970396.","DOI":"10.1056\/NEJMoa2024816"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827; PMID:\u00a027295427.","DOI":"10.1056\/NEJMoa1603827"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141; PMID:\u00a027633186.","DOI":"10.1056\/nejmoa1607141"},{"key":"ref65","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(Suppl 2):S1\u201345. https:\/\/doi.org\/10.1161\/01.cir.0000437738.63853.7a; PMID:\u00a024222016."},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174; PMID:\u00a030403574.","DOI":"10.1056\/NEJMoa1801174"},{"key":"ref67","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1501031; PMID:\u00a025773378."},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664; PMID:\u00a028304224.","DOI":"10.1056\/nejmoa1615664"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1316222; PMID:\u00a024678979.","DOI":"10.1056\/nejmoa1316222"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014;129:234\u201343. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.007012; PMID:\u00a024255061.","DOI":"10.1161\/circulationaha.113.007012"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380:1022\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1803917; PMID:\u00a030865796.","DOI":"10.1056\/nejmoa1803917"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA 2019;322:1780\u20138. https:\/\/doi.org\/10.1001\/jama.2019.16585; PMID:\u00a031714986.","DOI":"10.1001\/jama.2019.16585"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 2018;277:195\u2013203. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.002; PMID:\u00a029910030.","DOI":"10.1016\/j.atherosclerosis.2018.06.002"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc 2019;8:e011662. https:\/\/doi.org\/10.1161\/JAHA.118.011662; PMID:\u00a030922146.","DOI":"10.1161\/jaha.118.011662"},{"key":"ref75","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388:1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024; PMID:\u00a036876740."},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Battaggia A, Donzelli A, Font M, et al. Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS One 2015;10:e0124587. https:\/\/doi.org\/10.1371\/journal.pone.0124587; PMID:\u00a025915909.","DOI":"10.1371\/journal.pone.0124587"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Cholesterol Treatment Trialists\u2019 (Ctt) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5; PMID:\u00a021067804.","DOI":"10.1016\/s0140-6736(10)61350-5"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Wong ND, Zhao Y, Xiang P, et al. Five-year residual atherosclerotic cardiovascular disease risk prediction model for statin treated patients with known cardiovascular disease. Am J Cardiol 2020;137:7\u201311. https:\/\/doi.org\/10.1016\/j.amjcard.2020.09.043; PMID:\u00a032991855.","DOI":"10.1016\/j.amjcard.2020.09.043"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2019;4:846\u201354. https:\/\/doi.org\/10.1001\/jamacardio.2019.2306; PMID:\u00a031314050.","DOI":"10.1001\/jamacardio.2019.2306"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489; PMID:\u00a026039521.","DOI":"10.1056\/nejmoa1410489"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2022;80:1366\u2013418. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.006; PMID:\u00a036031461.","DOI":"10.1016\/j.jacc.2022.07.006"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Talasaz AH, Ho AJ, Bhatty F, et al. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. Pharmacotherapy 2021;41:1009\u201323. https:\/\/doi.org\/10.1002\/phar.2635; PMID:\u00a034657313.","DOI":"10.1002\/phar.2635"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Kazi DS, Penko J, Coxson PG, et al. Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med 2019;170:221\u20139. https:\/\/doi.org\/10.7326\/M18-1776; PMID:\u00a030597485.","DOI":"10.7326\/m18-1776"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: a state-of-the-art review. Pharmacotherapy 2025;45:54\u201365. https:\/\/doi.org\/10.1002\/phar.4635; PMID:\u00a039679827.","DOI":"10.1002\/phar.4635"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Gaine SP, Quispe R, Patel J, Michos ED. New strategies for lowering low-density lipoprotein cholesterol for cardiovascular disease prevention. Curr Cardiovasc Risk Rep 2022;16:69\u201378. https:\/\/doi.org\/10.1007\/s12170-022-00694-y; PMID:\u00a036213094.","DOI":"10.1007\/s12170-022-00694-y"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two Phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387; PMID:\u00a032187462.","DOI":"10.1056\/nejmoa1912387"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Kastelein JJP, Hsieh A, Dicklin MR, et al. Obicetrapib: reversing the tide of CETP inhibitor disappointments. Curr Atheroscler Rep 2024;26:35\u201344. https:\/\/doi.org\/10.1007\/s11883-023-01184-1; PMID:\u00a038133847.","DOI":"10.1007\/s11883-023-01184-1"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol 2024;9:800\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2024.1659; PMID:\u00a038958989.","DOI":"10.1001\/jamacardio.2024.1659"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42:e48\u201360. https:\/\/doi.org\/10.1161\/ATV.0000000000000147; PMID:\u00a034647487.","DOI":"10.1161\/atv.0000000000000147"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Berman AN, Biery DW, Besser SA, et al. Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease. J Am Coll Cardiol 2024;83:873\u201386. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.031; PMID:\u00a038418000.","DOI":"10.1016\/j.jacc.2023.12.031"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Small AM, Pournamdari A, Melloni GEM, et al. Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations. JAMA Cardiol 2024;9:e235605. https:\/\/doi.org\/10.1001\/jamacardio.2023.5605; PMID:\u00a038353970.","DOI":"10.1001\/jamacardio.2023.5605"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Nissen SE, Wang Q, Nicholls SJ, et al. Zerlasiran-A small-interfering RNA targeting lipoprotein(a): a Phase 2 randomized clinical trial. JAMA 2024;332:1992\u20132002. https:\/\/doi.org\/10.1001\/jama.2024.21957; PMID:\u00a039556769.","DOI":"10.1001\/jama.2024.21957"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Nicholls SJ, Ni W, Rhodes GM, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA 2025;333:e2424017. https:\/\/doi.org\/10.1001\/jama.2024.24017; PMID:\u00a039556768.","DOI":"10.1001\/jama.2024.24017"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Wong ND. Lipoprotein(a): ready for prime time? J Am Coll Cardiol 2024;83:887\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2024.01.004; PMID:\u00a038418001.","DOI":"10.1016\/j.jacc.2024.01.004"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2022;16:e77\u201395. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.007; PMID:\u00a036068139.","DOI":"10.1016\/j.jacl.2022.08.007"},{"key":"ref96","unstructured":"Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020;75:133\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.057; PMID:\u00a031948641."},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019;139:1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184; PMID:\u00a030586750.","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two\u2013year follow-up of the bezafibrate infarction prevention study and registry. Circ Cardiovasc Qual Outcomes 2016;9:100\u20138. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.115.002104; PMID:\u00a026957517.","DOI":"10.1161\/circoutcomes.115.002104"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Nichols GA, Philip S, Reynolds K, et al. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab 2019;21:366\u201371. https:\/\/doi.org\/10.1111\/dom.13537; PMID:\u00a030225881.","DOI":"10.1111\/dom.13537"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc 2018;7:e008740. https:\/\/doi.org\/10.1161\/JAHA.118.008740; PMID:\u00a030371242.","DOI":"10.1161\/jaha.118.008740"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 2018;72:330\u201343. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.061; PMID:\u00a029935936.","DOI":"10.1016\/j.jacc.2018.04.061"},{"key":"ref102","doi-asserted-by":"publisher","unstructured":"Malick WA, Waksman O, Do R, et al. Clinical trial design for triglyceride-rich lipoprotein-lowering therapies: JACC Focus Seminar 3\/3. J Am Coll Cardiol 2023;81:1646\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.034; PMID:\u00a037076219.","DOI":"10.1016\/j.jacc.2023.02.034"},{"key":"ref103","doi-asserted-by":"publisher","unstructured":"Gaba P, Bhatt DL, Mason RP, et al. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: a review of key findings from REDUCE-IT. J Clin Lipidol 2022;16:389\u2013402. https:\/\/doi.org\/10.1016\/j.jacl.2022.05.067; PMID:\u00a035773147.","DOI":"10.1016\/j.jacl.2022.05.067"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. Cardiovascular disease and risk management: standards of care in diabetes\u20142023. Diabetes Care 2023;46(Suppl 1):S158\u201390. https:\/\/doi.org\/10.2337\/dc23-S010; PMID:\u00a036507632.","DOI":"10.2337\/dc23-er04"},{"key":"ref105","doi-asserted-by":"publisher","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(07)60527-3; PMID:\u00a017398308.","DOI":"10.1016\/s0140-6736(07)60527-3"},{"key":"ref106","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792; PMID:\u00a030415628.","DOI":"10.1056\/nejmoa1812792"},{"key":"ref107","doi-asserted-by":"publisher","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020;324:2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258; PMID:\u00a033190147.","DOI":"10.1001\/jama.2020.22258"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Ridker PM, Rifai N, MacFadyen J, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1\u03b2, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation 2022;146:372\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059410; PMID:\u00a035762321.","DOI":"10.1161\/CIRCULATIONAHA.122.059410"},{"key":"ref109","doi-asserted-by":"publisher","unstructured":"Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl 2020;22(Suppl J):J34\u201348. https:\/\/doi.org\/10.1093\/eurheartj\/suaa117; PMID:\u00a033061866.","DOI":"10.1093\/eurheartj\/suaa117"},{"key":"ref110","doi-asserted-by":"publisher","unstructured":"Laffin LJ, Bruemmer D, Garcia M, et al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers. J Am Coll Cardiol 2023;81:1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.013; PMID:\u00a036351465.","DOI":"10.1016\/j.jacc.2022.10.013"},{"key":"ref111","doi-asserted-by":"publisher","unstructured":"Bangalore S, Fakheri R, Wandel S, et al. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 2017;356:j4. https:\/\/doi.org\/10.1136\/bmj.j4; PMID:\u00a028104622.","DOI":"10.1136\/bmj.j4"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation 2022;145:e895\u2013e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063; PMID:\u00a035363499.","DOI":"10.1161\/CIR.0000000000001073"},{"key":"ref113","doi-asserted-by":"publisher","unstructured":"Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126:e354\u2013471. https:\/\/doi.org\/10.1161\/CIR.0b013e318277d6a0; PMID:\u00a023166211.","DOI":"10.1161\/cir.0b013e318277d6a0"},{"key":"ref114","doi-asserted-by":"publisher","unstructured":"Goldstein S. Beta-blockers in hypertensive and coronary heart disease. Arch Intern Med 1996;156:1267\u201376. https:\/\/doi.org\/10.1001\/archinte.1996.00440110025005; PMID:\u00a08651834.","DOI":"10.1001\/archinte.1996.00440110025005"},{"key":"ref115","doi-asserted-by":"publisher","unstructured":"Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730\u20137. https:\/\/doi.org\/10.1136\/bmj.318.7200.1730; PMID:\u00a010381708.","DOI":"10.1136\/bmj.318.7200.1730"},{"key":"ref116","doi-asserted-by":"publisher","unstructured":"Bangalore S, Steg G, Deedwania P, et al. \u03b2-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340\u20139. https:\/\/doi.org\/10.1001\/jama.2012.12559; PMID:\u00a023032550.","DOI":"10.1001\/jama.2012.12559"},{"key":"ref117","doi-asserted-by":"publisher","unstructured":"Holt A, Blanche P, Zareini B, et al. Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. Eur Heart J 2021;42:907\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1058; PMID:\u00a033428707.","DOI":"10.1093\/eurheartj\/ehaa1058"},{"key":"ref118","doi-asserted-by":"publisher","unstructured":"Steg PG. Routine beta-blockers in secondary prevention \u2014 on injured reserve. N Engl J Med 2024;390:1434\u20136. https:\/\/doi.org\/10.1056\/NEJMe2402731; PMID:\u00a038587255.","DOI":"10.1056\/nejme2402731"},{"key":"ref119","doi-asserted-by":"crossref","unstructured":"Yndigegn T, Lindahl B, Mars K, et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med 2024;390:1372\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2401479; PMID:\u00a038587241.","DOI":"10.1056\/NEJMoa2401479"},{"key":"ref120","doi-asserted-by":"publisher","unstructured":"Flather MD, Yusuf S, K\u00f8ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(00)02212-1; PMID:\u00a010821360.","DOI":"10.1016\/s0140-6736(00)02212-1"},{"key":"ref121","doi-asserted-by":"publisher","unstructured":"K\u00f8ber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (TRACE) study group. N Engl J Med 1995;333:1670\u20136. https:\/\/doi.org\/10.1056\/NEJM199512213332503; PMID:\u00a07477219.","DOI":"10.1056\/nejm199512213332503"},{"key":"ref122","doi-asserted-by":"publisher","unstructured":"Pfeffer MA, Braunwald E, Moy\u00e9 LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669\u201377. https:\/\/doi.org\/10.1056\/NEJM199209033271001; PMID:\u00a01386652.","DOI":"10.1056\/nejm199209033271001"},{"key":"ref123","doi-asserted-by":"publisher","unstructured":"EURopean trial On reduction of cardiac events with\u00a0Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(03)14286-9; PMID:\u00a013678872.","DOI":"10.1016\/s0140-6736(03)14286-9"},{"key":"ref124","doi-asserted-by":"publisher","unstructured":"Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting\u2013enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145\u201353. https:\/\/doi.org\/10.1056\/NEJM200001203420301; PMID:\u00a010639539.","DOI":"10.1056\/nejm200001203420301"},{"key":"ref125","doi-asserted-by":"publisher","unstructured":"Pitt B, O\u2019Neill B, Feldman R, et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058\u201363. https:\/\/doi.org\/10.1016\/S0002-9149(01)01461-8; PMID:\u00a011348602.","DOI":"10.1016\/s0002-9149(01)01461-8"},{"key":"ref126","doi-asserted-by":"publisher","unstructured":"Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting\u2013enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058\u201368. https:\/\/doi.org\/10.1056\/NEJMoa042739; PMID:\u00a015531767.","DOI":"10.1056\/nejmoa042739"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J 2021;42:113\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa099; PMID:\u00a032176778.","DOI":"10.1093\/eurheartj\/ehaa099"},{"key":"ref128","doi-asserted-by":"crossref","unstructured":"Ridker PM. How common is residual inflammatory risk? Circ Res 2017;120:617\u20139. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.310527; PMID:\u00a028209792.","DOI":"10.1161\/CIRCRESAHA.116.310527"},{"key":"ref129","doi-asserted-by":"crossref","unstructured":"Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation 2018;138:131\u201340. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034032; PMID:\u00a029530884.","DOI":"10.1161\/CIRCULATIONAHA.118.034032"},{"key":"ref130","unstructured":"Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646; PMID:\u00a018997196."},{"key":"ref131","doi-asserted-by":"crossref","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914; PMID:\u00a028845751.","DOI":"10.1056\/NEJMoa1707914"},{"key":"ref132","doi-asserted-by":"publisher","unstructured":"Sehested TSG, Bjerre J, Ku S, et al. Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events. JAMA Cardiol 2019;4:128\u201335. https:\/\/doi.org\/10.1001\/jamacardio.2018.4566; PMID:\u00a030649147.","DOI":"10.1001\/jamacardio.2018.4566"},{"key":"ref133","doi-asserted-by":"crossref","unstructured":"Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019;380:752\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1809798; PMID:\u00a030415610.","DOI":"10.1056\/NEJMoa1809798"},{"key":"ref134","doi-asserted-by":"publisher","unstructured":"Wada Y, Jensen C, Meyer ASP, et al. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial. J Cardiol 2023;82:279\u201385. https:\/\/doi.org\/10.1016\/j.jjcc.2023.05.006; PMID:\u00a037211246.","DOI":"10.1016\/j.jjcc.2023.05.006"},{"key":"ref135","doi-asserted-by":"publisher","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2021;397:2060\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(21)00520-1; PMID:\u00a034015342.","DOI":"10.1016\/s0140-6736(21)00520-1"},{"key":"ref136","doi-asserted-by":"publisher","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.027; PMID:\u00a023265346.","DOI":"10.1016\/j.jacc.2012.10.027"},{"key":"ref137","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2021372; PMID:\u00a032865380."},{"key":"ref138","doi-asserted-by":"crossref","unstructured":"Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388; PMID:\u00a031733140.","DOI":"10.1056\/NEJMoa1912388"},{"key":"ref139","unstructured":"Jolly SS, d\u2019Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. N Engl J Med 2025;392:NEJMoa2405922. https:\/\/doi.org\/10.1056\/NEJMoa2405922; PMID:\u00a039555823."},{"key":"ref140","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1709118; PMID:\u00a028844192."},{"key":"ref141","unstructured":"Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(17)32409-1; PMID:\u00a029132880."},{"key":"ref142","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:205\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(17)32458-3; PMID:\u00a029132879."},{"key":"ref143","unstructured":"Bhatt DL, Eikelboom JW, Connolly SJ, et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial. Circulation 2020;141:1841\u201354. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.046448; PMID:\u00a032223318."},{"key":"ref144","unstructured":"Chow EJ, Rolfes MA, O\u2019Halloran A, et al. Acute cardiovascular events associated with influenza in hospitalized adults: a cross-sectional study. Ann Intern Med 2020;173:605\u201313. https:\/\/doi.org\/10.7326\/M20-1509; PMID:\u00a032833488."},{"key":"ref145","doi-asserted-by":"publisher","unstructured":"Aidoud A, Marlet J, Angoulvant D, et al. Influenza vaccination as a novel means of preventing coronary heart disease: effectiveness in older adults. Vaccine 2020;38:4944\u201355. https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.070; PMID:\u00a032536551.","DOI":"10.1016\/j.vaccine.2020.05.070"},{"key":"ref146","doi-asserted-by":"publisher","unstructured":"Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: a meta-analysis of case\u2013control studies. Heart 2015;101:1738\u201347. https:\/\/doi.org\/10.1136\/heartjnl-2015-307691; PMID:\u00a026310262.","DOI":"10.1136\/heartjnl-2015-307691"},{"key":"ref147","doi-asserted-by":"crossref","unstructured":"Clar C, Oseni Z, Flowers N, et al. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev 2015;2015:CD005050. https:\/\/doi.org\/10.1002\/14651858.CD005050.pub3; PMID:\u00a025940444.","DOI":"10.1002\/14651858.CD005050.pub3"},{"key":"ref148","doi-asserted-by":"publisher","unstructured":"Rodrigues BS, Alves M, Duarte GS, et al. The impact of influenza vaccination in patients with cardiovascular disease: an overview of systematic reviews. Trends Cardiovasc Med 2021;31:315\u201320. https:\/\/doi.org\/10.1016\/j.tcm.2020.06.003; PMID:\u00a032535214.","DOI":"10.1016\/j.tcm.2020.06.003"},{"key":"ref149","doi-asserted-by":"publisher","unstructured":"Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc 2021;10:e019636. https:\/\/doi.org\/10.1161\/JAHA.120.019636; PMID:\u00a033719496.","DOI":"10.1161\/jaha.120.019636"},{"key":"ref150","doi-asserted-by":"publisher","unstructured":"Fr\u00f6bert O, G\u00f6tberg M, Erlinge D, et al. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation 2021;144:1476\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057042; PMID:\u00a034459211.","DOI":"10.1161\/circulationaha.121.057042"},{"key":"ref151","doi-asserted-by":"crossref","unstructured":"Jiang J, Chan L, Kauffman J, et al. Impact of vaccination on major adverse cardiovascular events in patients with COVID-19 infection. J Am Coll Cardiol 2023;81:928\u201330. https:\/\/doi.org\/10.1016\/j.jacc.2022.12.006; PMID:\u00a036813689.","DOI":"10.1016\/j.jacc.2022.12.006"},{"key":"ref152","doi-asserted-by":"publisher","unstructured":"Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2015;132:873\u201398. https:\/\/doi.org\/10.1161\/CIR.0000000000000228; PMID:\u00a026240271.","DOI":"10.1161\/cir.0000000000000228"}],"container-title":["US Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.33","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T10:00:40Z","timestamp":1745920840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":153,"URL":"https:\/\/doi.org\/10.15420\/usc.2024.33","relation":{},"ISSN":["1758-390X","1758-3896"],"issn-type":[{"value":"1758-390X","type":"electronic"},{"value":"1758-3896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"e11"}}